By: Amit Chowdhry
Generate:Biomedicines - a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform - recently announced that it has raised $273 million in Series C financing. This funding round attracted many new investors including Amgen; NVentures, NVIDIA’s venture capital arm; MAPS Capital (Mirae Asset Group); and Pictet Alternative Advisors.